Methods: CD19 + CD24 hi CD38 hi Bregs were quantified in patients with atherosclerosis (myocardial infarction (MI), n=60; stable angina, SA, n=40), and in healthy subjects (n=30) using flow cytometry. Interleukin-10 (IL-10) production was quantified by intracellular staining.
Results:
The percentage and absolute number of circulating Bregs were markedly reduced in MI and SA patients compared to healthy subjects. No differences were noted in total, mature or memory B cells, suggesting a specific depletion of the Breg cell subset. Bregs from MI and SA patients produced significantly less IL-10 in response to CpG but not CD40L compared to Bregs from healthy subjects. IL-10 production by mature and memory B cells was not impaired. Molecular mechanisms that underlie defects in Bregs in patients with atherosclerosis are being characterised.
Conclusions:
Our data show for the first time that patients with atherosclerosis harbour marked numerical and functional defects in Breg cells that may tip the balance in favour of pro-inflammatory B and T lymphocytes. A better understanding of these defects may reveal novel targets for therapies to tackle inflammation in atherosclerosis.
